2022
Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery
Bakkila BF, Kerekes D, Nunez-Smith M, Billingsley KG, Ahuja N, Wang K, Oladele C, Johnson CH, Khan SA. Evaluation of Racial Disparities in Quality of Care for Patients With Gastrointestinal Tract Cancer Treated With Surgery. JAMA Network Open 2022, 5: e225664. PMID: 35377425, PMCID: PMC8980937, DOI: 10.1001/jamanetworkopen.2022.5664.Peer-Reviewed Original ResearchConceptsGastrointestinal tract cancerNegative resection marginsTract cancerNegative surgical marginsBlack patientsAdequate lymphadenectomyWhite patientsQuality of careRacial disparitiesSurgical resectionResection marginsSurgical marginsSurgical careNational Cancer DatabaseRetrospective cohort studySite of cancerLonger median survivalHealth careStandard of careCommon age rangeSignificant racial disparitiesAdjuvant chemotherapyBiliary resectionAdjuvant therapyAdult patients
2021
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O’Connor O. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 2021, 137: 2161-2170. PMID: 33171487, DOI: 10.1182/blood.2020009004.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaOverall response rateMedian progression-free survivalProgression-free survivalT-cell lymphomaOverall survivalR Peripheral T Cell LymphomaResponse rateFollicular helper cell phenotypeMulticenter phase 2 studyHigher overall response rateFrequent grade 3Complete response rateComplete remission ratePhase 2 studyPhase 1 trialDuration of responseHelper cell phenotypeLonger median survivalHistone deacetylase inhibitorsPTCL patientsR diseaseTreatment-naïveMedian survivalRemission rate
2016
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases
Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: 406-413. PMID: 27598807, PMCID: PMC5575932, DOI: 10.1016/j.ijrobp.2016.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsErbB ReceptorsFemaleGenetic MarkersGenetic Predisposition to DiseaseHumansIncidenceLung NeoplasmsMaleMiddle AgedMutationPolymorphism, Single NucleotidePrevalenceProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinasesRetrospective StudiesRisk FactorsSurvival RateUnited StatesConceptsTyrosine kinase inhibitionBrain metastasesMedian survivalCause of deathGene alterationsDiagnosis of BMMulti-institutional retrospective databaseTKI-naïve patientsRisk of deathLonger median survivalKinase inhibitionALK gene alterationsTreatment patternsCancer mortalityLung cancerPrimary diagnosisRetrospective databaseCommon causeLung adenocarcinomaGroup overallPatientsFirst treatmentPrior trialsEGFRMonths
2014
The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma
Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N, Rezaee N, Herman J, Zheng L, Laheru D, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL, Weiss MJ. The Impact of Postoperative Complications on the Administration of Adjuvant Therapy Following Pancreaticoduodenectomy for Adenocarcinoma. Annals Of Surgical Oncology 2014, 21: 2873-2881. PMID: 24770680, PMCID: PMC4454347, DOI: 10.1245/s10434-014-3722-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsPancreaticoduodenectomyPostoperative ComplicationsPrognosisRadiotherapy, AdjuvantRetrospective StudiesSurvival RateConceptsAdjuvant therapyPostoperative complicationsMedian survivalMultivariate analysisClavien-Dindo complication gradeTherapy warrants further investigationMultimodality adjuvant therapyOverall complication rateMethodsA retrospective reviewGrade of complicationsLonger median survivalLength of stayWarrants further investigationAdjuvant chemotherapyMedian TTANeoadjuvant approachComplication gradeComplication rateSevere complicationsRetrospective reviewClinicopathological dataResultsA totalPancreaticoduodenectomyRadiation therapyComplications
2013
Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clinical Cancer Research 2013, 19: 6633-6643. PMID: 24088734, PMCID: PMC4045641, DOI: 10.1158/1078-0432.ccr-13-0152.Peer-Reviewed Original ResearchMeSH KeywordsBlotting, WesternCarcinoma, Squamous CellCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p16DNA RepairDNA-Binding ProteinsEndonucleasesFemaleHead and Neck NeoplasmsHeLa CellsHumansImmunoprecipitationKaplan-Meier EstimateMaleNeoplasm Recurrence, LocalRetrospective StudiesTissue Array AnalysisTreatment OutcomeConceptsMedian survivalExcision Repair Cross-Complementing Group 1Low ERCC1 expressionSquamous cell headKaplan-Meier curvesSquamous cell carcinomaCisplatin-based therapyLonger median survivalERCC1 protein expressionInitial tumor presentationAdjuvant radiotherapyMultimodality treatmentRecurrent diseaseInitial presentationMultivariable analysisRecurrent cancerTumor presentationCell carcinomaHuman papillomavirusERCC1 expressionNeck cancerSurvival differencesCell headArchival tumorsGroup 1
2009
Outcomes of Malignant CNS Ependymomas: An Examination of 2408 Cases Through the Surveillance, Epidemiology, and End Results (SEER) Database (1973–2005)
Rodríguez D, Cheung MC, Housri N, Quinones-Hinojosa A, Camphausen K, Koniaris LG. Outcomes of Malignant CNS Ependymomas: An Examination of 2408 Cases Through the Surveillance, Epidemiology, and End Results (SEER) Database (1973–2005). Journal Of Surgical Research 2009, 156: 340-351. PMID: 19577759, PMCID: PMC7371344, DOI: 10.1016/j.jss.2009.04.024.Peer-Reviewed Original ResearchConceptsEnd Results (SEER) databaseSurgical resectionCNS ependymomasMedian survivalResults databaseRadiation therapyMultivariate analysisIntracranial tumor locationOverall median survivalRole of surgeryFive-year survivalSignificant survival benefitLonger median survivalGrade III tumorsPrimary tumor siteLack of radiationMedian agePatient ageSurvival benefitImproved survivalIndependent predictorsAnnual incidenceMalignant ependymomaSurgical extirpationPatient survival
2008
Malignant abdominal mesothelioma: Defining the role of surgery
Rodríguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: Defining the role of surgery. Journal Of Surgical Oncology 2008, 99: 51-57. PMID: 18942074, DOI: 10.1002/jso.21167.Peer-Reviewed Original ResearchConceptsRole of surgerySurgical resectionMedian survivalDifferentiated tumor gradePotential surgical resectionOverall median survivalEnd Results (SEER) databaseLonger median survivalLocalized diseaseYounger patientsIndependent predictorsAnnual incidenceResults databasePoor outcomeSurgical extirpationMale genderMalignant mesotheliomaTumor gradeAdvanced ageAbdominal mesotheliomaPatientsMultivariate analysisResectionSurvivalSignificant differences
1978
Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy
Young R, Chabner B, Hubbard S, Fisher R, Bender R, Anderson T, Simon R, Canellos G, DeVita V. Advanced Ovarian Adenocarcinoma — A Prospective Clinical Trial of Melphalan (L-PAM) versus Combination Chemotherapy. New England Journal Of Medicine 1978, 299: 1261-1266. PMID: 101843, DOI: 10.1056/nejm197812072992301.Peer-Reviewed Original ResearchConceptsAdvanced ovarian adenocarcinomaFour-drug combinationOverall response rateOvarian adenocarcinomaComplete remissionMedian survivalResidual diseaseResponse rateHigher overall response rateExtensive residual diseaseFour-drug regimenProspective clinical trialsLonger median survivalMinimal residual diseaseAdvanced diseaseCombination chemotherapyClinical trialsSevere toxicityMelphalanPatientsAdenocarcinomaDiseaseRemissionTrialsSurvival
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply